{"success":true,"data":{"pressRelease":{"id":"3321","rtpr_id":"nGNX1bRXj","ticker":"GOSS","exchange":"NASDAQ","all_tickers":["GOSS"],"title":"Deadline Alert: Gossamer Bio, Inc. (GOSS) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit","author":"Globe Newswire","published_at":"2026-04-21T16:33:27.107Z","article_body":"LOS ANGELES, April 21, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter\nLLP\n(https://www.globenewswire.com/Tracker?data=rVmORUAkFCeaGj7s6Qgj41O7AB4vSqiy_BwWzBAaEx9sHjQvRKScPVJI_LI19xDre5Aksij_lqJJDvq92iIcyZghQJnZQvdm90cfELIe3KHMTtxLk3iiyRVeITs8Vxgh)\nreminds investors of the upcoming June 1, 2026 deadline to file a lead\nplaintiff motion in the class action filed on behalf of investors who\npurchased or otherwise acquired Gossamer Bio, Inc. (“Gossamer” or the\n“Company”) (NASDAQ: GOSS\n(https://www.globenewswire.com/Tracker?data=KwmT1Ur9HyFv7A0FDLjBiS3xWgaYl2p7sIL7JMe4uwqBNbsFeTgKI-xokMC525SrGpj1jjHYr4k72p24PZYx8PmqFbWqwhOVzMTEJ5yeZtE=))\nsecurities between June 16, 2025 and February 20, 2026, inclusive (the\n“Class Period”).\n\nIF YOU SUFFERED A LOSS ON YOUR GOSSAMER INVESTMENTS, CLICK HERE\n(https://www.globenewswire.com/Tracker?data=2WkgLHWCBFJPaa9z6uAcJUpyvVqMB_T1dSYPSEmLEW6cZVAV7OG2pdwX0sFuhPN7aA1FN3065IT_HLWf4uPgVkXmK2zKFOnmifzNpgGj62k=)\nTO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS UNDER THE\nFEDERAL SECURITIES LAWS.\n\nWhat Happened? \nOn February 23, 2026, Gossamer disclosed that results for its Phase 3 PROSERA\nstudy of seralutinib for the treatment of pulmonary arterial hypertension had\nfailed to meet the primary endpoint, citing patients at Latin American sites\nperforming particularly well on placebo due to enrollment of a heavily-treated\nlower-risk population.\n\nOn this news, Gossamer’s stock price fell $1.71, or 80.3%, to close at $0.42\nper share on February 23, 2026, thereby injuring investors.\n\nWhat Is The Lawsuit About? \nThe complaint filed in this class action alleges that throughout the Class\nPeriod, Defendants made materially false and/or misleading statements, as well\nas failed to disclose material adverse facts about the Company’s business,\noperations, and prospects. Specifically, Defendants failed to disclose to\ninvestors that: (1) patients at the Latin American sites were largely\nheavily-treated and lower risk and, ultimately, performed particularly well on\nthe placebo, thus, Gossamer’s Phase 3 PROSERA study failed to meet the\nprimary endpoint of improved six-minute walk distance at week 24; and (2) as a\nresult, Defendants’ positive statements about the Company’s business,\noperations, and prospects were materially misleading and/or lacked a\nreasonable basis at all relevant times.\n\nIf you purchased or otherwise acquired Gossamer securities during the Class\nPeriod, you may move the Court no later than June 1, 2026 to request\nappointment as lead plaintiff in this putative class action lawsuit.\n\nContact Us To Participate or Learn More: \nIf you wish to learn more about this action, or if you have any questions\nconcerning this announcement or your rights or interests with respect to these\nmatters, please contact us: \nCharles Linehan, Esq., \nGlancy Prongay Wolke & Rotter LLP,\n1925 Century Park East, Suite 2100, \nLos Angeles California 90067 \nEmail:  shareholders@glancylaw.com \nTelephone: 310-201-9150, \nToll-Free: 888-773-9224 \nVisit our website at www.glancylaw.com. \nFollow us for updates on LinkedIn\n(https://www.globenewswire.com/Tracker?data=-_hATsExSm0h8tyIwbFAuSPbmvi8U76gv4rsjwHYulTleNJJwR9WXoOx3oMhhCzw1sru2LYj1Ihv0MCW1RnNlJjH_O_taS5UO4S-B9qTjMderbmb8Tl6pdGFfqWoicTv),\nTwitter\n(https://www.globenewswire.com/Tracker?data=MH4qLPKN2M2j9nlo0Qa9tRsi7qKLPb6RPCWo141UGRAew7R4koPdNXE-FPSU1ym0DctoFSIHo5-DWF9UWZe5KQ==),\nor Facebook\n(https://www.globenewswire.com/Tracker?data=EQHwZHHS7qUy2DixAfveslOQDOo1a961glKa7z7xYLBC7goJkvrhtXJHj34FQHVj0IbPV0FxrHoer7Ufptlq8hwFYFxtXFOXQF0ixT8HkiE=).\n\nIf you inquire by email, please include your mailing address, telephone number\nand number of shares purchased.\n\nTo be a member of the class action you need not take any action at this time;\nyou may retain counsel of your choice or take no action and remain an absent\nmember of the class action. This press release may be considered Attorney\nAdvertising in some jurisdictions under the applicable law and ethical rules.\n\nContact Us: \nGlancy Prongay Wolke & Rotter LLP, \n1925 Century Park East, Suite 2100\nLos Angeles, CA 90067 \nCharles Linehan\nEmail:  shareholders@glancylaw.com \nTelephone: 310-201-9150\nToll-Free: 888-773-9224 \nVisit our website at: www.glancylaw.com.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/a67368e9-bc06-4c5b-a902-dd2d9af3e4f0)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX1bRXj","title":"Deadline Alert: Gossamer Bio, Inc. (GOSS) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit","author":"Globe Newswire","ticker":"GOSS","created":"2026-04-21T16:33:27.107Z","tickers":["GOSS"],"exchange":"NASDAQ","article_body":"LOS ANGELES, April 21, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter\nLLP\n(https://www.globenewswire.com/Tracker?data=rVmORUAkFCeaGj7s6Qgj41O7AB4vSqiy_BwWzBAaEx9sHjQvRKScPVJI_LI19xDre5Aksij_lqJJDvq92iIcyZghQJnZQvdm90cfELIe3KHMTtxLk3iiyRVeITs8Vxgh)\nreminds investors of the upcoming June 1, 2026 deadline to file a lead\nplaintiff motion in the class action filed on behalf of investors who\npurchased or otherwise acquired Gossamer Bio, Inc. (“Gossamer” or the\n“Company”) (NASDAQ: GOSS\n(https://www.globenewswire.com/Tracker?data=KwmT1Ur9HyFv7A0FDLjBiS3xWgaYl2p7sIL7JMe4uwqBNbsFeTgKI-xokMC525SrGpj1jjHYr4k72p24PZYx8PmqFbWqwhOVzMTEJ5yeZtE=))\nsecurities between June 16, 2025 and February 20, 2026, inclusive (the\n“Class Period”).\n\nIF YOU SUFFERED A LOSS ON YOUR GOSSAMER INVESTMENTS, CLICK HERE\n(https://www.globenewswire.com/Tracker?data=2WkgLHWCBFJPaa9z6uAcJUpyvVqMB_T1dSYPSEmLEW6cZVAV7OG2pdwX0sFuhPN7aA1FN3065IT_HLWf4uPgVkXmK2zKFOnmifzNpgGj62k=)\nTO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS UNDER THE\nFEDERAL SECURITIES LAWS.\n\nWhat Happened? \nOn February 23, 2026, Gossamer disclosed that results for its Phase 3 PROSERA\nstudy of seralutinib for the treatment of pulmonary arterial hypertension had\nfailed to meet the primary endpoint, citing patients at Latin American sites\nperforming particularly well on placebo due to enrollment of a heavily-treated\nlower-risk population.\n\nOn this news, Gossamer’s stock price fell $1.71, or 80.3%, to close at $0.42\nper share on February 23, 2026, thereby injuring investors.\n\nWhat Is The Lawsuit About? \nThe complaint filed in this class action alleges that throughout the Class\nPeriod, Defendants made materially false and/or misleading statements, as well\nas failed to disclose material adverse facts about the Company’s business,\noperations, and prospects. Specifically, Defendants failed to disclose to\ninvestors that: (1) patients at the Latin American sites were largely\nheavily-treated and lower risk and, ultimately, performed particularly well on\nthe placebo, thus, Gossamer’s Phase 3 PROSERA study failed to meet the\nprimary endpoint of improved six-minute walk distance at week 24; and (2) as a\nresult, Defendants’ positive statements about the Company’s business,\noperations, and prospects were materially misleading and/or lacked a\nreasonable basis at all relevant times.\n\nIf you purchased or otherwise acquired Gossamer securities during the Class\nPeriod, you may move the Court no later than June 1, 2026 to request\nappointment as lead plaintiff in this putative class action lawsuit.\n\nContact Us To Participate or Learn More: \nIf you wish to learn more about this action, or if you have any questions\nconcerning this announcement or your rights or interests with respect to these\nmatters, please contact us: \nCharles Linehan, Esq., \nGlancy Prongay Wolke & Rotter LLP,\n1925 Century Park East, Suite 2100, \nLos Angeles California 90067 \nEmail:  shareholders@glancylaw.com \nTelephone: 310-201-9150, \nToll-Free: 888-773-9224 \nVisit our website at www.glancylaw.com. \nFollow us for updates on LinkedIn\n(https://www.globenewswire.com/Tracker?data=-_hATsExSm0h8tyIwbFAuSPbmvi8U76gv4rsjwHYulTleNJJwR9WXoOx3oMhhCzw1sru2LYj1Ihv0MCW1RnNlJjH_O_taS5UO4S-B9qTjMderbmb8Tl6pdGFfqWoicTv),\nTwitter\n(https://www.globenewswire.com/Tracker?data=MH4qLPKN2M2j9nlo0Qa9tRsi7qKLPb6RPCWo141UGRAew7R4koPdNXE-FPSU1ym0DctoFSIHo5-DWF9UWZe5KQ==),\nor Facebook\n(https://www.globenewswire.com/Tracker?data=EQHwZHHS7qUy2DixAfveslOQDOo1a961glKa7z7xYLBC7goJkvrhtXJHj34FQHVj0IbPV0FxrHoer7Ufptlq8hwFYFxtXFOXQF0ixT8HkiE=).\n\nIf you inquire by email, please include your mailing address, telephone number\nand number of shares purchased.\n\nTo be a member of the class action you need not take any action at this time;\nyou may retain counsel of your choice or take no action and remain an absent\nmember of the class action. This press release may be considered Attorney\nAdvertising in some jurisdictions under the applicable law and ethical rules.\n\nContact Us: \nGlancy Prongay Wolke & Rotter LLP, \n1925 Century Park East, Suite 2100\nLos Angeles, CA 90067 \nCharles Linehan\nEmail:  shareholders@glancylaw.com \nTelephone: 310-201-9150\nToll-Free: 888-773-9224 \nVisit our website at: www.glancylaw.com.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/a67368e9-bc06-4c5b-a902-dd2d9af3e4f0)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-04-21T16:33:27.148829394Z","server_sent_at_ms":1776789207148},"received_at":"2026-04-21T16:33:27.206Z","source_url":"https://www.globenewswire.com/news-release/2026/04/21/3278289/0/en/deadline-alert-gossamer-bio-inc-goss-shareholders-who-lost-money-urged-to-contact-glancy-prongay-wolke-rotter-llp-about-securities-fraud-lawsuit.html"},"analysis":{"id":"2218","press_release_id":"3321","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":["Securities fraud class action lawsuit","Phase 3 PROSERA study failed to meet primary endpoint","Stock dropped 80.3% on news of trial failure"],"eventType":"legal_litigation","narrative":"Glancy Prongay Wolke & Rotter LLP reminded investors of the June 1, 2026 deadline to file a lead plaintiff motion in a class action lawsuit against Gossamer Bio.\n\nThe lawsuit alleges securities fraud related to the company's statements about the Phase 3 PROSERA study of seralutinib for pulmonary arterial hypertension.\n\nOn February 23, 2026, Gossamer disclosed the trial failed to meet its primary endpoint, causing the stock to drop $1.71, or 80.3%, to close at $0.42.","sentiment":"bearish","agentHooks":{"shouldPost":true,"suggestedAngle":"Legal pressure mounts on GOSS as investors are urged to join a class action over the failed seralutinib trial."},"keyFigures":{"drugName":"seralutinib","phaseOfTrial":"Phase 3"},"quotedText":"Gossamer’s stock price fell $1.71, or 80.3%, to close at $0.42 per share on February 23, 2026, thereby injuring investors.","namedEntities":{"people":[{"name":"Charles Linehan","role":"Esq."}],"products":["seralutinib"],"companies":[{"name":"Glancy Prongay Wolke & Rotter LLP","relationship":"plaintiff counsel"},{"name":"Gossamer Bio, Inc.","ticker":"GOSS"}],"dollarAmounts":[{"amount":"$1.71","context":"stock price drop on February 23, 2026"},{"amount":"$0.42","context":"closing stock price on February 23, 2026"}]},"materialImpact":{"score":4,"reasoning":"The announcement involves a securities fraud class action lawsuit related to a failed Phase 3 trial that caused an 80% stock price collapse. While the clinical failure was the primary market-moving event, the lawsuit represents significant ongoing legal and financial liability."},"tickerRelevance":{"others":[],"primary":"GOSS"},"eventTypeSecondary":["clinical_trial"]},"event_type":"legal_litigation","event_type_secondary":["clinical_trial"],"sentiment":"bearish","material_impact_score":4,"narrative":"Glancy Prongay Wolke & Rotter LLP reminded investors of the June 1, 2026 deadline to file a lead plaintiff motion in a class action lawsuit against Gossamer Bio.\n\nThe lawsuit alleges securities fraud related to the company's statements about the Phase 3 PROSERA study of seralutinib for pulmonary arterial hypertension.\n\nOn February 23, 2026, Gossamer disclosed the trial failed to meet its primary endpoint, causing the stock to drop $1.71, or 80.3%, to close at $0.42.","key_figures":{"drugName":"seralutinib","phaseOfTrial":"Phase 3"},"named_entities":{"people":[{"name":"Charles Linehan","role":"Esq."}],"products":["seralutinib"],"companies":[{"name":"Glancy Prongay Wolke & Rotter LLP","relationship":"plaintiff counsel"},{"name":"Gossamer Bio, Inc.","ticker":"GOSS"}],"dollarAmounts":[{"amount":"$1.71","context":"stock price drop on February 23, 2026"},{"amount":"$0.42","context":"closing stock price on February 23, 2026"}]},"model_name":"glm-4.7","prompt_hash":"sha256:2f2748f0fcc8c4f2","schema_hash":"sha256:ad96b863d7123008","created_at":"2026-04-21T22:22:52.810Z","global_importance":3,"audience_relevance":3,"importance_components":{"method":"backfill-heuristic","signals":{"bodyLong":false,"headlineTier1":false,"tickerCovered":false,"hadSignificance":false},"version":1,"computedAt":"2026-04-27T11:52:53.635Z"}},"durationMs":72066,"modelName":"glm-4.7"}}